Pioglitazone is a PPARγ agonist that significantly increased the antioxidant response in fibroblasts from patients and in the knock-in/knock out (KIKO) FRDA mouse model by promoting the expression of SOD2 and PGC-1α [149]. Here, PPARG is linked to Friedreich ataxia.